Ipeleng Kgosiemang-Xaba | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Ipeleng Kgosiemang-Xaba
University of the Free State, South Africa
Ipeleng Kgosiemang-Xaba
Affiliation University of the Free State
Country South Africa
Scopus ID 56707418000
Documents 9
Citations 241
h-index 7
Subject Area Oncology
Event Health Scientists Awards

Ipeleng Kgosiemang-Xaba is presented in this academic recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions.[1]

Abstract

Ipeleng Kgosiemang-Xaba is presented in this recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions. The profile therefore highlights an interdisciplinary trajectory centered on biologically active South African plants, cancer-related mechanisms, and translational opportunities while maintaining a neutral distinction between documented scientific outputs and award recognition.[3]

Keywords

Euphorbia species; cancer; medicinal plants; pharmacological properties; toxicity; secondary metabolites; breast cancer; antiproliferative activity; iron oxide nanoparticles; iron dioxide nanoparticles; natural-product pharmacology; phytochemicals. These terms are aligned particularly with the publication literature addressing Southern African Euphorbia species and experimental anticancer research.[2]

Introduction

Ipeleng Kgosiemang-Xaba’s research profile reflects an interdisciplinary interest in oncology, medicinal plants, pharmacology, and biomedical technology. Her publications address Euphorbia-derived bioactive compounds and experimental anticancer approaches, including nanoparticle systems evaluated against breast cancer cell lines. These themes place natural-product research within a framework of cancer research and translational biomedical investigation.[1]

Research Profile

Ipeleng Kgosiemang-Xaba has published work spanning molecular biology, medicinal plants, phytochemistry, pharmacology, and oncology. Her research includes studies of Euphorbia species and their secondary metabolites, together with experimental investigations of antiproliferative effects and nanoparticle-mediated approaches. The available literature indicates a continuing interest in linking biological resources with therapeutic research questions.[2][3]

Research Contributions

Ipeleng Kgosiemang-Xaba’s contributions include systematic examination of Southern African Euphorbia species, their medicinal uses, toxicity, phytochemical constituents, and reported pharmacological activities. Her research also includes green synthesis of iron-based nanoparticles using Euphorbia tirucalli and evaluation of antiproliferative activity against breast cancer cell lines, thereby connecting plant science with experimental oncology.[2][3]

Publications

Ipeleng Kgosiemang-Xaba is associated with publications addressing Euphorbia pharmacology, anticancer research, nanoparticle synthesis, and molecular biology. A 2025 review in Plants examined medicinal uses, toxicity, secondary metabolites, and pharmacological properties of Southern African Euphorbia species, while a 2023 Journal of Experimental Nanoscience article evaluated iron-based nanoparticles and breast cancer models.[5]

Research Impact

Ipeleng Kgosiemang-Xaba’s research impact can be considered through the relevance of her publications to natural-product pharmacology, cancer biology, and biomedical nanotechnology. Her work contributes evidence on underexplored Southern African plant resources and experimental anticancer strategies. Citation activity and publication visibility provide measurable indicators, while broader clinical significance requires further validation.[3]

Award Suitability

Ipeleng Kgosiemang-Xaba’s documented research themes are compatible with an Innovative Research Award focused on oncology, natural-product discovery, and biomedical technology. Her publications demonstrate research activity involving anticancer constituents, Euphorbia species, phytochemicals, and nanoparticle systems. Award suitability should remain subject to the event’s published formal criteria, independent verification, and comparative assessment.[4]

Conclusion

Ipeleng Kgosiemang-Xaba presents a research profile connecting Southern African medicinal plants with pharmacology, nanotechnology, and oncology. Her publications provide evidence of work on Euphorbia chemistry, toxicity, antiproliferative activity, and cancer-oriented experimental systems. Collectively, these outputs support recognition of an emerging interdisciplinary research direction without implying clinical efficacy beyond published evidence.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Ipeleng Kgosiemang-Xaba, Author ID 56707418000. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56707418000
  2. Kgosiemang, I. K. R., Lefojane, R., Adegoke, A. M., Ogunyemi, O., Mashele, S. S., & Sekhoacha, M. P. (2025). Pharmacological significance, medicinal use, and toxicity of extracted and isolated compounds from Euphorbia species found in Southern Africa: A review. Plants, 14(3), 469.https://doi.org/10.3390/plants14030469
  3. Kgosiemang, I. K. R., Adegoke, A. M., Mashele, S. S., & Sekhoacha, M. P. (2023). Green synthesis of iron oxide and iron dioxide nanoparticles using Euphorbia tirucalli: Characterization and antiproliferative evaluation against three breast cancer cell lines. Journal of Experimental Nanoscience, 18(1), 2276276.https://doi.org/10.1080/17458080.2023.2276276
  4. Parvez, M., Qhanya, L. B., Mthakathi, N. T., Kgosiemang, I. K. R., et al. (2016). Molecular evolutionary dynamics of cytochrome P450 monooxygenases across kingdoms: Special focus on mycobacterial P450s. Scientific Reports, 6, 33099.https://doi.org/10.1038/srep33099
  5. Kgosiemang, I. K. R. (2024). Targeted delivery of iron, cobalt and magnesium nanoparticles incorporating anticancer constituents of Euphorbia species for treatment of breast cancer. Doctor of Health Sciences in Biomedical Technology, Central University of Technology, Free State.https://cutscholar.cut.ac.za/items/e527142e-a8dc-4c94-8eb1-121facf1eff7/full

Aimaz Afrough | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Aimaz Afrough
UT Southwestern Medical Center, United States

Aimaz Afrough
Affiliation UT Southwestern Medical Center
Country United States
Scopus ID 43660943000
Documents 63
Citations 1,171
h-index 19
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0003-2645-8557

Aimaz Afrough is a researcher affiliated with UT Southwestern Medical Center whose scholarly work primarily focuses on oncology, molecular cancer biology, translational medicine, and clinically relevant cancer investigations. The research portfolio reflects sustained contributions to understanding tumor biology, improving diagnostic approaches, and supporting evidence-based therapeutic development. Publications indexed in major scientific databases demonstrate active participation in multidisciplinary cancer research while promoting scientific collaboration and clinical translation within contemporary oncology research.[1]

Abstract

Aimaz Afrough investigates oncology through multidisciplinary research integrating molecular biology, translational medicine, cancer diagnostics, and therapeutic innovation. Published studies emphasize clinically meaningful discoveries that improve understanding of tumor development, disease progression, biomarker identification, and treatment response. The research demonstrates collaboration across biomedical disciplines while supporting evidence-based clinical practice and precision oncology. Scientific publications indexed in recognized databases contribute to advancing cancer research, strengthening translational applications, encouraging interdisciplinary collaboration, and providing valuable knowledge that informs future investigations, patient-centered healthcare strategies, and sustainable improvements in oncology outcomes worldwide.[2]

Keywords

Oncology, Cancer Biology, Tumor Microenvironment, Precision Oncology, Molecular Oncology, Cancer Biomarkers, Translational Medicine, Immuno-Oncology, Clinical Oncology, Cancer Therapeutics

Introduction

Aimaz Afrough contributes to oncology research by investigating biological mechanisms underlying cancer and translating laboratory discoveries into clinically meaningful knowledge. Research activities strengthen interdisciplinary collaboration while supporting innovative diagnostic methods, precision medicine, and therapeutic development that improve understanding of complex malignancies across diverse healthcare environments.[3]

Research Profile

Aimaz Afrough maintains an academic profile centered on oncology, emphasizing molecular mechanisms, translational investigations, biomarker discovery, and collaborative biomedical research. Publications demonstrate commitment to scientific rigor while addressing clinically relevant questions that support evidence generation and continuous advancement of modern cancer research and healthcare innovation.[1]

Research Contributions

Aimaz Afrough has contributed to collaborative investigations exploring cancer biology, translational oncology, molecular diagnostics, and therapeutic strategies. Research findings enhance scientific understanding of disease mechanisms while supporting precision medicine initiatives, improving clinical interpretation, and encouraging continued innovation across multidisciplinary oncology research communities worldwide.[4]

Publications

Aimaz Afrough has authored and coauthored peer-reviewed publications indexed within recognized scientific databases. Published studies address oncology, molecular medicine, and translational research while reflecting sustained scholarly engagement, interdisciplinary collaboration, methodological quality, and contributions supporting scientific communication, clinical relevance, and future biomedical investigation.[2]

Research Impact

Aimaz Afrough demonstrates measurable research impact through scholarly publications, scientific collaborations, and dissemination within oncology. The research supports evidence-based medicine, encourages knowledge exchange, informs future investigations, and contributes valuable insights that strengthen translational cancer research and broader biomedical scientific advancement internationally.[1]

Award Suitability

Aimaz Afrough demonstrates qualifications appropriate for consideration within the Innovative Research Award through consistent oncology research, interdisciplinary collaboration, scholarly publications, and contributions supporting translational medicine. Scientific activities reflect innovation, academic integrity, and continuing commitment to advancing biomedical knowledge through evidence-based cancer research.[5]

Conclusion

Aimaz Afrough continues contributing to oncology through collaborative scientific research emphasizing translational relevance, molecular discoveries, and clinical applicability. Continued scholarly activities strengthen biomedical knowledge, encourage innovation, support evidence-based healthcare, and provide meaningful foundations for future advances within international oncology research communities.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Aimaz Afrough, Author ID 43660943000. Scopus.
    https://www.scopus.com/pages/authors/43660943000
  2. ORCID. (n.d.). Aimaz Afrough ORCID Record.
    https://orcid.org/0000-0003-2645-8557
  3. Google Scholar. (n.d.). Scholar Profile: Aimaz Afrough.
    https://scholar.google.com/citations?user=2ENlGnkAAAAJ&hl=en&oi=ao
  4. ResearchGate. (n.d.). Aimaz Afrough Research Profile.
    https://www.researchgate.net/profile/Aimaz-Afrough
  5. Health Scientists Awards. (n.d.). Innovative Research Award.
    https://healthscientists.org/

Rasha Elsabagh | Oncology | Research Excellence Award

Published on by Health Scientists

Dr. Rasha Elsabagh | Oncology | Research Excellence Award

Researcher | Animal Health Research Institute(AHRI) | Egypt

Rasha H. Elsabagh is a multidisciplinary immunology specialist and cancer stem cell researcher with extensive expertise spanning stem cell biology, immuno-oncology, translational cancer research, and veterinary biomedical sciences. She currently serves as a researcher at the Animal Health Research Institute, where her work integrates advanced immunological diagnostics, molecular biology, and national livestock immunization programs that directly contribute to animal health surveillance and disease control. Her academic training culminated in a doctoral degree in cancer immunology from Cairo University, where her research focused on circulating cancer stem cells and photothermal nanotherapy as predictive and monitoring tools for tumor response. She has conducted advanced international research training at University of California San Francisco, gaining high-level proficiency in flow cytometry, immunofluorescence, and human stem cell analysis, and later expanded her translational oncology experience as a visiting research fellow at the Cancer Institute of Montpellier, working on nanoparticle-mediated RNA delivery to tumor-infiltrating immune cells. Her scientific output includes multiple peer-reviewed publications in high-impact journals and international conference proceedings, with her work receiving sustained scholarly citations and global academic recognition. Her research collaborations span institutions in North America, Europe, and the Middle East, reflecting her active role in international scientific networks in stem cell biology, cancer immunology, and nanomedicine. Beyond laboratory research, she contributes to national capacity building through scientific training, quality assurance in diagnostic immunology, and public health–oriented animal disease control programs. Her work has direct societal impact through improvements in cancer diagnostics, advancement of immunotherapeutic strategies, and strengthening of zoonotic disease surveillance, positioning her as a globally engaged scientist at the intersection of experimental research, translational medicine, and public health. She has 2 citations from 2 documents with an h-index of 1.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Xiao, T., Eze, U. C., Charruyer-Reinwald, A., Weisenberger, T., Khalifa, A., … (2024). Short cell cycle duration is a phenotype of human epidermal stem cells. Stem Cell Research & Therapy, 15(1), 76.

2. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Ragab, E., … (2021). Quantitative flow cytometry assessment of feline circulatory breast cancer stem cells. Advances in Animal and Veterinary Sciences, 9(12), 2201–2215.

3. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H. H., Ragab, E., … (2025). Gold nano-rod (AuNR)-mediated plasmonic photothermal therapy in feline mammary carcinoma: Assessing metastatic and nonmetastatic outcomes. Veterinary Oncology, 2(1), 33.

4. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H., Ragab, E., … (2022). Prevention of in situ recurrence and distant metastasis in feline mammary carcinoma treated with plasmonic photothermal therapy.